secwatch / observer
8-K filed March 18, 2022, 7:59 PM ET ticker SYRE CIK 0001636282
leadership confidence high sentiment neutral materiality 0.30

Aeglea Bio's VP/Controller Steven Weber resigns; CFO Alspaugh named principal accounting officer

Spyre Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Steven Weber

Vice President and Corporate Controller
SYRE · Spyre Therapeutics, Inc.
Effective
2022-03-25
Successor
Jonathan Alspaugh
Filed
March 18, 2022, 7:59 PM ET
On March 16, 2022, Steven Weber, the Vice President and Corporate Controller of Aeglea Biotherapeutics, Inc. (the “Company”), and the Company’s principal accounting officer, notified the Company that he will be resigning from his positions, effective March 25, 2022.
Appointed

Jonathan Alspaugh

Principal Accounting Officer
SYRE · Spyre Therapeutics, Inc.
Effective
2022-03-17
Filed
March 18, 2022, 7:59 PM ET
On March 17, 2022, the Company appointed Jonathan Alspaugh, age 39, Chief Financial Officer, as its principal accounting officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Weber resigned as Vice President and Corporate Controller at Spyre Therapeutics, Inc..

Action
resigned
Role
Vice President and Corporate Controller
Exact text from the filing
On March 16, 2022, Steven Weber, the Vice President and Corporate Controller of Aeglea Biotherapeutics, Inc. (the “Company”), and the Company’s principal accounting officer, notified the Company that he will be resigning from his positions, effective March 25, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Alspaugh was appointed as Principal Accounting Officer at Spyre Therapeutics, Inc..

Action
appointed
Role
Principal Accounting Officer
Exact text from the filing
On March 17, 2022, the Company appointed Jonathan Alspaugh, age 39, Chief Financial Officer, as its principal accounting officer, effective immediately.
View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001564590-22-010951
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.